Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

por Harrison, Stephen A., Bashir, Mustafa, Moussa, Sam E., McCarty, Kevin, Pablo Frias, Juan, Taub, Rebecca, Alkhouri, Naim
Publicado 2021

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

por Harrison, Stephen A., Taub, Rebecca, Neff, Guy W., Lucas, K. Jean, Labriola, Dominic, Moussa, Sam E., Alkhouri, Naim, Bashir, Mustafa R.
Publicado 2023